Therapeutic effect of prostaglandin E1 in monocrotaline-induced pulmonary arterial hypertension rats

Abstract

Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular disease characterized by sustained increase in pulmonary arterial pressure and excessive thickening and remodeling of distal small pulmonary arteries. During disease progression, PAH include increase in mean pulmonary arterial pressure, right ventricular (RV) enlargement, increased pulmonary vascular resistance, and smooth muscle hypertrophy in pulmonary arterioles. Several anti-PAH therapies targeting various pathways involved in PAH progression have been approved by the Food and Drug Adminstration. However, many of the currently available anti-PAH drugs suffer from a number of limitations, including short biological half-life, and poor pulmonary selectivity. Prostaglandin E1 (PGE1) is a potent vasodilator with selectivity toward pulmonary circulation when it is administered via the pulmonary route. However, PGE1 has a very short half-life of 5–10 minutes. Therefore, we hypothesized that long-term effect of PGE1 could reduce mal-adaptive structural remodeling of the lung and heart and prevent ventricular arrhythmias in monocrotaline-induced rat model of PAH. Our results revealed that PGE1 reduced ventricular hypertrophy, protein expressions of endothelin-1 and endothelin receptor A, and the expression of fibrosis. These results support the notion that PGE1 can improve the functional properties of RV, highlighting its potential benefits for heart and lung impairment.

Prostaglandin E1 Alleviates Cognitive Dysfunction in Chronic Cerebral Hypoperfusion Rats by Improving Hemodynamics

“…Because PGE1 is a well-known potent vasodilator (Hasegawa and Ichioka, 2015; Lee, 2017). To investigate whether the enhancement of CBF and cognitive functions by PGE1 was attributed to vascular alteration, we examined the effect of PGE1 on vertebral arteries (VAs).…”

The Role of Hormones and Trophic Factors as Components of Preservation Solutions in Protection of Renal Function before Transplantation: A Review of the Literature

“…Activation of the EP3 receptor (so-called “inhibitory”) reduces the level of cyclic adenosine monophosphate (cAMP), whereas the EP2 and EP4 receptors (so-called “relaxing”) increase the level of cAMP [ 95 , 96 ]. PGE1 has strong vasodilatory, anti-inflammatory, anti-proliferative properties, is a strong platelet aggregation inhibitor, stimulates smooth muscles, reduces platelet hyperactivity and thromboxane A2 (TXA2) level, reduces free Ca 2+ levels in vascular smooth myocytes [ 97 , 98 ]. It has been found that PGE1 influences the maintenance of renal hemodynamic homeostasis by regulating blood flow and distribution as well as electrolyte and water excretion [ 99 ].…”

Retraction notice to “Therapeutic effect of prostaglandin E1 in monocrotaline-induced pulmonary arterial hypertension rats” by Lee JC (Anat Cell Biol 2017;50:60-8)

“…The article [ 1 ] has been retracted at the request of the editor and author due to the following reasons: Research Ethics Committee of the Korean Association of Anatomists confirmed (1) the author submitted the false information about the author's affiliation and (2) the author duplicated the Institutional Review Board (IRB) number. The author apologizes to the readers.…”